2025-05-19

Efficacy of compound embryonic bovine liver extract in hepatitis B related liver cirrhosis

To investigate the effect of compound embryonic bovine liver extract in patients with hepatitis B related liver cirrhosis.

2025-05-19

Effects of treatment with entecavir or combination of entecavir and thymosin on the values of APRI and LSM of patients with chronic hepatitis B accompanied by liver fibrosis

The antiviral treatment regimen was optimized by comparing the efficacy of ETV and ETV combined with Thyα-a on CHB patients with liver fibrosis which was reflected by the values of APRI, LSM and HBV-DNA in serums.

2025-05-19

Efficacy of entecavir and peg-IFNα-2a or thymosin α1 combination in the treatment of patient with compensated hepatitis B liver cirrhosis

To evaluate the efficacy of entecavir and PEG-IFNα-2a or thymosin α1 combination in the treatment of patient with compensated hepatitis B liver cirrhosis.

2025-05-19

Clinical effect of ursodeoxycholic acid combined with diammonium glycyrrhizinate in treatment of primary biliary cholangitis

To investigate the clinical effect of ursodeoxycholic acid(UDCA) alone or in combination with diammonium glycyrrhizinate on biochemical response and liver stiffness measurement (LSM) in the treatment of primary biliary cholangitis (PBC).

2025-05-19

Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia (IF=6.7)

To evaluate the effectiveness and safety of switching from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in ETV-treated patients with low-level viraemia (LLV).

2025-05-19

Efficacy of tauroursodeoxycholic acid combined with polyene phosphatidylcholine in the treatment of non-alcoholic fatty liver disease

To evaluate the efficacy and safety of tauroursodeoxycholic acid combined with polyene phosphatidylcholine in the treatment of non-alcoholic fatty liver disease (NAFLD).

2025-05-19

Effects of shenmai lanling decoction on liver fat content and liver fibrosis in patients with type 2 diabetes mellitus combined with non-alcoholic fatty liver disease

To observe the effect of Shenmai Lanling Decoction on liver fat content and liver fibrosis in patients with type 2 diabetes mellitus (T2DM) combined with non-alcoholic fatty liver disease (NAFLD).

2025-05-19

A 3-year follow-up of patients with serum HBeAg-positive chronic hepatitis B after 48 to 72 week pegylated interferon α-2a treatment

The aim of this study was to investigate the 3-year follow-up results of patients with serum HBeAg-positive chronic hepatitis B (CHB) after 48 to 72 week pegylated interferon α-2a (peg-IFN α-2a) treatment.